ADHD
MCID: ATT013
MIFTS: 69

Attention Deficit-Hyperactivity Disorder (ADHD) malady

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder

Aliases & Descriptions for Attention Deficit-Hyperactivity Disorder:

Name: Attention Deficit-Hyperactivity Disorder 54 51
Attention Deficit Hyperactivity Disorder 39 12 29 41 14 69
Adhd 39 12 51 3 14
Attention Deficit Disorder 12 52 69
Attention-Deficit/hyperactivity Disorder, Predominantly Inattentive Type 69
Attention Deficit-Hyperactivity Disorder, Susceptibility to 13
Attention Deficit Disorder with Hyperactivity 42
Attention-Deficit Hyperactivity Disorder 52
Hyperkinetic Disorder 12

Characteristics:

HPO:

32
attention deficit-hyperactivity disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 143465
Disease Ontology 12 DOID:1094
ICD9CM 35 314.8
MeSH 42 D001289
NCIt 47 C35092
ICD10 33 F90 F90.0 F90.9

Summaries for Attention Deficit-Hyperactivity Disorder

MedlinePlus : 41 is it hard for your child to sit still? does your child act without thinking first? does your child start but not finish things? if so, your child may have attention deficit hyperactivity disorder (adhd). nearly everyone shows some of these behaviors at times, but adhd lasts more than 6 months and causes problems in school, at home and in social situations. adhd is more common in boys than girls. it affects 3-5 percent of all american children. the main features of adhd are inattention hyperactivity impulsivity no one knows exactly what causes adhd. it sometimes runs in families, so genetics may be a factor. there may also be environmental factors. a complete evaluation by a trained professional is the only way to know for sure if your child has adhd. treatment may include medicine to control symptoms, therapy, or both. structure at home and at school is important. parent training may also help. nih: national institute of mental health

MalaCards based summary : Attention Deficit-Hyperactivity Disorder, also known as attention deficit hyperactivity disorder, is related to autism spectrum disorder and personality disorder, and has symptoms including attention deficit hyperactivity disorder, hyperactivity and back pain. An important gene associated with Attention Deficit-Hyperactivity Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Circadian entrainment and Neuroscience. The drugs Dextroamphetamine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and cardiovascular system

Disease Ontology : 12 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone\

CDC : 3 Fill out the symptoms checklist and share it with the child’s doctor.

NINDS : 51 Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.

Wikipedia : 71 Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It... more...

Description from OMIM: 143465

Related Diseases for Attention Deficit-Hyperactivity Disorder

Diseases related to Attention Deficit-Hyperactivity Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
id Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 31.5 COMT DRD4 DRD5 MECP2 SLC6A2 SLC6A3
2 personality disorder 31.2 COMT DRD3 DRD4 MAOA MECP2 SLC6A2
3 schizophrenia 31.1 ADRA2A COMT DBH DRD3 DRD4 DRD5
4 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.6
5 attention deficit-hyperactivity disorder susceptibility, adhd4-related 12.3
6 attention deficit-hyperactivity disorder susceptibility, drd4-related 12.3
7 attention deficit-hyperactivity disorder susceptibility, drd5-related 12.3
8 aarskog-scott syndrome 11.6
9 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.3
10 pol iii-related leukodystrophies 11.3
11 cerebral creatine deficiency syndrome 1 11.1
12 impulse control disorder 11.1
13 chromosome 16p11.2 deletion syndrome, 220-kb body mass index quantitative trait locus 16, included 11.1
14 chromosome 15q11.2 deletion syndrome 11.1
15 gilles de la tourette syndrome 11.1
16 epilepsy, focal, with speech disorder and with or without mental retardation 11.1
17 chromosome 1q21.1 deletion syndrome 11.1
18 thyroid hormone resistance 11.1
19 landau-kleffner syndrome 11.0
20 williams-beuren syndrome 10.8
21 conduct disorder 10.8
22 basal ganglia disease 10.7
23 oppositional defiant disorder 10.7
24 tic disorder 10.6
25 developmental coordination disorder 10.5
26 bipolar disorder 10.5
27 pervasive developmental disorder 10.5
28 learning disability 10.5
29 obesity 10.5
30 rectosigmoid junction neoplasm 10.4 DRD4 DRD5 SLC6A3 TPH2
31 c8 deficiency, type ii 10.4 COMT DRD3 DRD4
32 anodontia 10.4 HTR1B SLC6A3 SLC6A4
33 intrahepatic gall duct cancer 10.4 COMT MAOA SLC6A4 TPH2
34 nephrogenic adenoma of the urethra 10.4 DBH SLC6A2 SLC6A3 SLC6A4
35 alzheimer disease 17 10.4 DRD3 DRD4 SLC6A4 TPH2
36 pyromania 10.4 DRD3 DRD4 MAOA SLC6A3 SLC6A4
37 kidney pelvis papillary carcinoma 10.4 MAOA SLC6A2 SLC6A4
38 tinea pedis 10.4 MAOA SLC6A3 SLC6A4
39 transmitted_by 10.4 DBH DRD3 SLC6A3 SLC6A4
40 strongyloidiasis 10.4 COMT MAOA SLC6A3 SLC6A4 SNAP25
41 chronic eosinophilic pneumonia 10.4 COMT MAOA SLC6A4
42 carotid stenosis 10.4 COMT DRD4 DRD5 MAOA SLC6A3 SLC6A4
43 littre gland carcinoma 10.4 HTR1B SLC6A2 SLC6A3
44 keratosis 10.4 COMT MAOA SLC6A2 SLC6A4 TPH2
45 renpenning syndrome 10.4 COMT DBH HTR1B MAOA SLC6A4
46 multiple personality disorder 10.4 COMT HTR1B MAOA SLC6A4 TPH2
47 cholesteatoma 10.4 COMT SLC6A3 SLC6A4
48 fechtner syndrome 10.4 COMT MAOA SLC6A2 SLC6A4 TPH2
49 aortic valve disease 2 10.4 ADRA2A COMT DBH DRD4 DRD5 SLC6A3
50 brain glioblastoma multiforme 10.4 COMT DRD3 SLC6A3 SLC6A4 TPH2

Graphical network of the top 20 diseases related to Attention Deficit-Hyperactivity Disorder:



Diseases related to Attention Deficit-Hyperactivity Disorder

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder

Symptoms by clinical synopsis from OMIM:

143465

Clinical features from OMIM:

143465

Human phenotypes related to Attention Deficit-Hyperactivity Disorder:

32
id Description HPO Frequency HPO Source Accession
1 attention deficit hyperactivity disorder 32 HP:0007018
2 hyperactivity 32 HP:0000752

UMLS symptoms related to Attention Deficit-Hyperactivity Disorder:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Attention Deficit-Hyperactivity Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 DRD5 HTR1B MAOA MECP2 SLC6A2 SLC6A3
2 cardiovascular system MP:0005385 10.03 MAOA MECP2 SLC6A2 SLC6A4 SNAP25 TPH2
3 homeostasis/metabolism MP:0005376 9.93 ADRA2A COMT DBH DRD3 DRD4 MAOA
4 nervous system MP:0003631 9.8 ADRA2A COMT DBH DOCK3 DRD3 DRD4
5 normal MP:0002873 9.23 ADRA2A DBH DRD5 MECP2 SLC6A3 SLC6A4

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder

Drugs for Attention Deficit-Hyperactivity Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dextroamphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 51-64-9 5826
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
4
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
5
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
6
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2 29110-47-2 3519
7
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
8
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
9
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
10
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
11
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
12
Sertraline Approved Phase 4 79617-96-2 68617
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
15
Clonidine Approved Phase 4,Phase 3,Phase 2 4205-90-7 2803
16 Piracetam Approved Phase 4 7491-74-9
17
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
18
Methamphetamine Approved, Illicit Phase 4,Phase 2 537-46-2 10836
19
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 300-62-9 5826 3007
20
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
21
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
22
Memantine Approved, Investigational Phase 4 19982-08-2 4054
23
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
24
Nicotine Approved Phase 4,Phase 3,Phase 1 54-11-5 942 89594
25
Milnacipran Approved Phase 4 92623-85-3 65833
26
Cyproheptadine Approved Phase 4 129-03-3 2913
27
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 75614-87-8, 51-45-6 774
28
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 112111-43-0
29
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 68693-11-8 4236
30
Carbon monoxide Approved Phase 4 630-08-0 281
31
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
32
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
33
Oxcarbazepine Approved Phase 4 28721-07-5 34312
34
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
35
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 73-31-4 896
36 tannic acid Approved, Nutraceutical Phase 4,Phase 3
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-02-9 14985
38 Anticonvulsants Phase 4,Phase 3
39 Antimanic Agents Phase 4,Phase 3
40 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
42 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 GABA Agents Phase 4,Phase 3
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
48
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
49 Serotonin Agents Phase 4,Phase 3,Phase 2
50 Serotonin Antagonists Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 1052)
id Name Status NCT ID Phase
1 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4
2 Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder Unknown status NCT01130467 Phase 4
3 Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties Unknown status NCT01393574 Phase 4
4 Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children Unknown status NCT00754208 Phase 4
5 Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents Unknown status NCT00536419 Phase 4
6 Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD Unknown status NCT02074228 Phase 4
7 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4
8 Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD Unknown status NCT01709695 Phase 4
9 Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD) Unknown status NCT00862108 Phase 4
10 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4
11 Attention Deficit Disorder Medication Response Study Unknown status NCT01727414 Phase 4
12 Lisdexamfetamine's Effect In ADHD in the Brain and Cognition Unknown status NCT02170298 Phase 4
13 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4
14 Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Unknown status NCT00252278 Phase 4
15 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
16 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4
17 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4
18 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4
19 Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation Unknown status NCT01924429 Phase 4
20 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4
21 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4
22 An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT01060150 Phase 4
23 Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01069523 Phase 4
24 An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01012622 Phase 4
25 Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00937040 Phase 4
26 A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder Completed NCT00190931 Phase 4
27 The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00758160 Phase 4
28 A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Completed NCT00471354 Phase 4
29 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4
30 Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder Completed NCT01439126 Phase 4
31 Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder Completed NCT01552915 Phase 4
32 Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder Completed NCT01552902 Phase 4
33 Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00783835 Phase 4
34 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4
35 The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder Completed NCT00773916 Phase 4
36 Neuroimaging of the Effects of Concerta in the Treatment of ADHD Completed NCT00778310 Phase 4
37 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4
38 A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants Completed NCT01933880 Phase 4
39 Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children Completed NCT01065259 Phase 4
40 Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder Completed NCT00866996 Phase 4
41 Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00546910 Phase 4
42 Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children Completed NCT00254462 Phase 4
43 Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder Completed NCT00429273 Phase 4
44 Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study) Completed NCT00889915 Phase 4
45 Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD) Completed NCT00842127 Phase 4
46 A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder Completed NCT00518232 Phase 4
47 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. Completed NCT01873729 Phase 4
48 Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01238822 Phase 4
49 Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder Completed NCT01831622 Phase 4
50 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: attention deficit disorder with hyperactivity

Genetic Tests for Attention Deficit-Hyperactivity Disorder

Genetic tests related to Attention Deficit-Hyperactivity Disorder:

id Genetic test Affiliating Genes
1 Attention Deficit Hyperactivity Disorder 29

Anatomical Context for Attention Deficit-Hyperactivity Disorder

MalaCards organs/tissues related to Attention Deficit-Hyperactivity Disorder:

39
Brain, Testes, Eye, Heart, Thyroid, Cortex, Amygdala

Publications for Attention Deficit-Hyperactivity Disorder

Articles related to Attention Deficit-Hyperactivity Disorder:

(show top 50) (show all 1383)
id Title Authors Year
1
Nutritional Status of Korean Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD). ( 28503507 )
2017
2
Evaluation of Knowledge and Attitude of Parents of Attention Deficit/Hyperactivity Disorder Children towards Attention Deficit/Hyperactivity Disorder in Clinical Samples. ( 28496501 )
2017
3
The relationship of social anxiety disorder symptoms with probable attention deficit hyperactivity disorder in Turkish university students; impact of negative affect and personality traits of neuroticism and extraversion. ( 28460287 )
2017
4
Attention-Deficit Hyperactivity Disorder (ADHD) Symptoms in Children Adopted from Poland and their Atypical Association Patterns: a Bayesian Approach. ( 28523385 )
2017
5
Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism. ( 28072412 )
2017
6
Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. ( 28052720 )
2017
7
Editorial: The continuing contributions of multimodal treatment of attention over nearly two decades to initial attention-deficit hyperactivity disorder pharmacotherapy and long-term clinical course. ( 28524461 )
2017
8
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495551 )
2017
9
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults - Authors' reply. ( 28495548 )
2017
10
Prestimulus Inhibition of Saccades in Adults With and Without Attention-Deficit/Hyperactivity Disorder as an Index of Temporal Expectations. ( 28520552 )
2017
11
Vineland-II adaptive behavior profile of children with attention-deficit/hyperactivity disorder or specific learning disorders. ( 28056381 )
2017
12
Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment. ( 28492426 )
2017
13
Auditory Processing Assessment in Children with Attention Deficit Hyperactivity Disorder: An Open Study Examining Methylphenidate Effects. ( 28050211 )
2017
14
Diagnostic utility of brain activity flow patterns analysis in attention deficit hyperactivity disorder. ( 28065167 )
2017
15
Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder. ( 27561780 )
2017
16
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. ( 28073796 )
2017
17
Shared and disorder-specific task-positive and default mode network dysfunctions during sustained attention in paediatric Attention-Deficit/Hyperactivity Disorder and obsessive/compulsive disorder. ( 28529874 )
2017
18
Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review. ( 28493018 )
2017
19
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495550 )
2017
20
Sleep problems in children with attention-deficit hyperactivity disorder: associations with parenting style and sleep hygiene. ( 28509968 )
2017
21
Early high school engagement in students with attention/deficit hyperactivity disorder. ( 28054712 )
2017
22
Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD). ( 28534274 )
2017
23
Differential therapeutic effects of atomoxetine and methylphenidate in childhood attention deficit/hyperactivity disorder as measured by near-infrared spectroscopy. ( 28507595 )
2017
24
Attention-deficit/hyperactivity disorder (ADHD): from randomised controlled trials to evidence-based clinical services. ( 28065196 )
2017
25
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. ( 28501733 )
2017
26
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495552 )
2017
27
Cognitive profiles of adults with high-functioning autism spectrum disorder and those with attention-deficit/hyperactivity disorder based on the WAIS-III. ( 28064024 )
2017
28
Distracted Driving With Attention-Deficit/Hyperactivity Disorder. ( 28492867 )
2017
29
Cognitively and physically demanding exergaming to improve executive functions of children with attention deficit hyperactivity disorder: a randomised clinical trial. ( 28068954 )
2017
30
Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. ( 28492937 )
2017
31
Attention-deficit/hyperactivity disorder symptoms and psychological comorbidity in eating disorder patients. ( 28534123 )
2017
32
Handedness and Attention Deficit/Hyperactivity Disorder Symptoms in College Students. ( 28508302 )
2017
33
Iron Status in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. ( 28046016 )
2017
34
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495546 )
2017
35
A systematic review of circadian function, chronotype and chronotherapy in attention deficit hyperactivity disorder. ( 28064405 )
2017
36
Association of pediatric allergic rhinitis with the ratings of attention-deficit/hyperactivity disorder. ( 28490400 )
2017
37
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
38
Co-morbidity in Attention-Deficit Hyperactivity Disorder: A Clinical Study from India. ( 28053283 )
2016
39
Sleep disorder investigation might be considered to be mandatory in attention deficit/hyperactivity disorder guideline. ( 27706417 )
2016
40
Mild head injury and attention deficit hyperactivity disorder in children. ( 27568372 )
2016
41
Investigative and therapeutic uses of Transcranial magnetic stimulation (TMS) in Attention Deficit Hyperactivity Disorder (ADHD). ( 27663816 )
2016
42
Hyperactivity in motor response inhibition networks in unmedicated children with attention deficit hyperactivity disorder. ( 27648848 )
2016
43
Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. ( 27663942 )
2016
44
MAP1B and NOS1 genes are associated with working memory in youths with attention-deficit/hyperactivity disorder. ( 26233433 )
2016
45
Mediating and Moderating Role of Depression, Conduct Disorder or Attention-Deficit/Hyperactivity Disorder in Developing Adolescent Substance Use Disorders: A Population-Based Study. ( 27294778 )
2016
46
Attention deficit-hyperactivity disorder is associated with reduced blood pressure and serum vitamin D levels: results from the nationwide German Health Interview and Examination Survey for Children and Adolescents (KiGGS). ( 27197525 )
2016
47
Relationship between acne vulgaris and attention-deficit/hyperactivity disorder symptoms in a clinical sample of women. ( 27192533 )
2016
48
Development of social anxiety disorder secondary to attention deficit/hyperactivity disorder (the developmental hypothesis). ( 27585496 )
2016
49
Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms. ( 27183902 )
2016
50
Epigenetic regulation of the DRD4 gene and dimensions of attention-deficit/hyperactivity disorder in children. ( 26897359 )
2016

Variations for Attention Deficit-Hyperactivity Disorder

ClinVar genetic disease variations for Attention Deficit-Hyperactivity Disorder:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MECP2 NM_001110792.1(MECP2) indel Pathogenic rs786205019 GRCh37 Chromosome X, 153296095: 153296115
2 GNB5 NM_006578.3(GNB5): c.242C> T (p.Ser81Leu) single nucleotide variant Pathogenic/Likely pathogenic rs761399728 GRCh38 Chromosome 15, 52153947: 52153947
3 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh38 Chromosome 6, 12123884: 12123884
4 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh37 Chromosome 9, 90584834: 90584834

Copy number variations for Attention Deficit-Hyperactivity Disorder from CNVD:

7 (show top 50) (show all 84)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 34465 1 56053497 56064495 Deletion USP24 Attention deficit hyperactivity disorder
2 34466 1 56053497 56064495 Deletion USP24e Attention deficit hyperactivity disorder
3 36125 1 72317292 72328395 Duplication NEGR1 Attention deficit hyperactivity disorder
4 49516 11 107520009 107885084 Duplication C11orf65 Attention deficit hyperactivity disorder
5 49517 11 107520009 107885084 Duplication EXPH5 Attention deficit hyperactivity disorder
6 49518 11 107520009 107885084 Duplication KDELC2 Attention deficit hyperactivity disorder
7 60337 11 85300000 92300000 Deletion GRM5 Attention deficit hyperactivity disorder
8 60583 11 88269449 88351661 Deletion GRM5 Attention deficit hyperactivity disorder
9 60585 11 88269449 88351661 Het ACAT1 Attention deficit hyperactivity disorder
10 60586 11 88269449 88351661 Het ATM Attention deficit hyperactivity disorder
11 60587 11 88269449 88351661 Het GRM5 Attention deficit hyperactivity disorder
12 60588 11 88269449 88351661 Het NPAT Attention deficit hyperactivity disorder
13 63163 12 115300000 116700000 Duplicated NOS1 Attention deficit hyperactivity disorder
14 69603 12 55902280 55923860 Deletion NDUFA4L2 Attention deficit hyperactivity disorder
15 69604 12 55902280 55923860 Deletion NXPH4 Attention deficit hyperactivity disorder
16 69605 12 55902280 55923860 Deletion SHMT2 Attention deficit hyperactivity disorder
17 69606 12 55902280 55923860 Deletion STAC3 Attention deficit hyperactivity disorder
18 75846 13 24844208 25493420 Duplication or delet ion ATP8A2 Attention deficit hyperactivity disorder
19 76965 13 38815028 39075356 Duplication or delet ion LHFP Attention deficit hyperactivity disorder
20 78033 13 48967801 49001118 Duplication or delet ion PHF11 Attention deficit hyperactivity disorder
21 78043 13 49004082 49057720 Duplication or delet ion RCBTB1 Attention deficit hyperactivity disorder
22 79472 13 72254230 72488592 Duplication or delet ion PIBF1 Attention deficit hyperactivity disorder
23 91412 15 30110017 30248527 Deletion CHRNA7 Attention deficit hyperactivity disorder
24 99563 16 27600000 34400000 Deleted ERK1 Attention deficit hyperactivity disorder
25 99685 16 28100000 34600000 Deletion CORO1A Attention deficit hyperactivity disorder
26 101713 16 45500000 51200000 Duplicated ZNF423 Attention deficit hyperactivity disorder
27 103489 16 6072599 6783832 Duplication A2BP1 Attention deficit hyperactivity disorder
28 106366 16 87694595 87778383 Deletion CDH15 Attention deficit hyperactivity disorder
29 109330 17 25613604 26191779 Duplication BLMH Attention deficit hyperactivity disorder
30 117083 17 71112486 71120734 Deletion Attention deficit hyperactivity disorder
31 122044 18 52000000 54400000 Duplicated NEDD4L Attention deficit hyperactivity disorder
32 123018 18 65358832 65367619 Deletion DOK6 Attention deficit hyperactivity disorder
33 125924 19 15992679 15997923 Deletion LOC126536 Attention deficit hyperactivity disorder
34 127980 19 38427720 38444834 Deletion SLC7A10 Attention deficit hyperactivity disorder
35 127981 19 38427720 38444834 Deletion SLC7A10e Attention deficit hyperactivity disorder
36 132645 19 59423491 59428132 Duplication LILRB3 Attention deficit hyperactivity disorder
37 132646 19 59423491 59428132 Duplication LIR-3 Attention deficit hyperactivity disorder
38 136696 2 132200000 134800000 Deleted NAP5 Attention deficit hyperactivity disorder
39 139372 2 1792886 2335045 Duplication or delet ion MYT1L Attention deficit hyperactivity disorder
40 146272 2 47600000 52700000 Deleted NRXN1 Attention deficit hyperactivity disorder
41 146517 2 50145643 51259674 Duplication or delet ion NRXN1 Attention deficit hyperactivity disorder
42 146826 2 55088956 55239201 Duplication RTN4 Attention deficit hyperactivity disorder
43 148301 2 75400000 83700000 Deleted CTNNA2 Attention deficit hyperactivity disorder
44 148598 2 81419297 81446082 Duplication CTNNA2 Attention deficit hyperactivity disorder
45 148599 2 81419297 81446082 Duplication CTNNA2e Attention deficit hyperactivity disorder
46 154924 20 5000000 9000000 Deleted BMP2 Attention deficit hyperactivity disorder
47 164095 22 34870070 34916870 Het APOL3 Attention deficit hyperactivity disorder
48 164096 22 34870070 34916870 Het APOL4 Attention deficit hyperactivity disorder
49 164674 22 38384374 38403731 Deletion CACNA1I Attention deficit hyperactivity disorder
50 166998 3 111722434 117006477 Deletion Attention deficit hyperactivity disorder

Expression for Attention Deficit-Hyperactivity Disorder

Search GEO for disease gene expression data for Attention Deficit-Hyperactivity Disorder.

Pathways for Attention Deficit-Hyperactivity Disorder

Pathways related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 COMT DRD3 DRD4 DRD5 MAOA SLC6A3
2 12.39 COMT DBH MECP2 SNAP25 TPH2
4 11.93 MAOA MECP2 SLC6A4 SNAP25 TPH2
5 11.81 HTR1B MAOA SLC6A4 TPH2
6
Show member pathways
11.74 DRD3 DRD4 SNAP25
7
Show member pathways
11.72 ADRA2A DRD3 DRD4 DRD5 HTR1B
8
Show member pathways
11.58 COMT DBH MAOA
9
Show member pathways
11.35 COMT SLC6A2 SLC6A4
10 10.94 ADRA2A DBH SLC6A2
11 10.9 HTR1B MAOA SLC6A4 TPH2
12
Show member pathways
10.89 COMT DBH MAOA
13
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
14 10.69 COMT MAOA
15
Show member pathways
10.69 COMT MAOA SLC6A3 SLC6A4
16
Show member pathways
10.68 COMT MAOA

GO Terms for Attention Deficit-Hyperactivity Disorder

Cellular components related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 ADRA2A DRD3 DRD4 DRD5 HTR1B SLC6A2
2 postsynapse GO:0098794 9.13 DRD4 MECP2 SNAP25
3 neuron projection GO:0043005 9.02 SLC6A2 SLC6A3 SLC6A4 SNAP25 TPH2

Biological processes related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

(show all 39)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 COMT DRD3 HTR1B SLC6A2 SLC6A3 SLC6A4
2 response to ethanol GO:0045471 9.85 DRD3 HTR1B SLC6A3
3 cellular calcium ion homeostasis GO:0006874 9.83 DRD3 DRD4 DRD5
4 locomotory behavior GO:0007626 9.83 DBH DRD3 SLC6A3 SNAP25
5 memory GO:0007613 9.77 DBH MECP2 SLC6A4
6 visual learning GO:0008542 9.77 DBH DRD3 MECP2
7 neurotransmitter transport GO:0006836 9.76 SLC6A2 SLC6A3 SLC6A4
8 learning GO:0007612 9.73 COMT DRD3 DRD5 MECP2
9 chemical synaptic transmission GO:0007268 9.73 DBH DRD5 HTR1B MECP2 SLC6A2 SNAP25
10 associative learning GO:0008306 9.72 DBH DRD5 SNAP25
11 negative regulation of adenylate cyclase activity GO:0007194 9.71 ADRA2A DRD3 DRD4
12 social behavior GO:0035176 9.71 DRD3 DRD4 MECP2 SLC6A4
13 response to pain GO:0048265 9.69 COMT DBH SLC6A2
14 regulation of dopamine secretion GO:0014059 9.68 DRD3 HTR1B
15 behavioral response to cocaine GO:0048148 9.67 DRD3 DRD4
16 dopamine receptor signaling pathway GO:0007212 9.67 DRD3 DRD4
17 vasoconstriction GO:0042310 9.67 HTR1B SLC6A4
18 negative regulation of cAMP biosynthetic process GO:0030818 9.67 ADRA2A DRD4 HTR1B
19 synaptic transmission, dopaminergic GO:0001963 9.66 DRD3 DRD5
20 behavioral response to ethanol GO:0048149 9.65 DBH DRD4
21 neurotransmitter biosynthetic process GO:0042136 9.65 SLC6A3 SLC6A4
22 ammonium transmembrane transport GO:0072488 9.65 SLC6A3 SLC6A4
23 dopamine metabolic process GO:0042417 9.65 COMT DRD3 DRD4
24 prepulse inhibition GO:0060134 9.64 DRD3 SLC6A3
25 negative regulation of protein secretion GO:0050709 9.64 DRD3 DRD4
26 G-protein coupled receptor internalization GO:0002031 9.63 DRD3 HTR1B
27 neurotransmitter catabolic process GO:0042135 9.63 COMT MAOA
28 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.62 DRD3 DRD4
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.62 DRD3 DRD5
30 response to cocaine GO:0042220 9.62 DRD3 DRD5 HTR1B SLC6A3
31 catecholamine metabolic process GO:0006584 9.61 COMT MAOA
32 regulation of dopamine metabolic process GO:0042053 9.61 DRD4 SLC6A3
33 fear response GO:0042596 9.58 DBH DRD4
34 cellular biogenic amine metabolic process GO:0006576 9.57 MAOA MECP2
35 response to histamine GO:0034776 9.56 DRD3 DRD4
36 monoamine transport GO:0015844 9.54 SLC6A2 SLC6A3 SLC6A4
37 dopamine uptake involved in synaptic transmission GO:0051583 9.33 SLC6A2 SLC6A3 SLC6A4
38 response to amphetamine GO:0001975 9.26 DBH DRD3 DRD4 DRD5
39 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.8 ADRA2A DRD3 DRD4 DRD5 HTR1B
2 symporter activity GO:0015293 9.63 SLC6A2 SLC6A3 SLC6A4
3 drug binding GO:0008144 9.62 DRD3 DRD4 HTR1B SLC6A3
4 syntaxin-1 binding GO:0017075 9.48 SLC6A4 SNAP25
5 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
6 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A2 SLC6A3 SLC6A4
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD3 DRD4
8 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD3 DRD4 DRD5
9 dopamine:sodium symporter activity GO:0005330 9.13 SLC6A2 SLC6A3 SLC6A4
10 dopamine binding GO:0035240 8.92 DRD3 DRD4 DRD5 SLC6A3

Sources for Attention Deficit-Hyperactivity Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....